Literature DB >> 12404887

Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study.

Eiko E Petersen1, Ernst R Weissenbacher, Peter Hengst, Heinz Spitzbart, Wolfgang Weise, Friedrich Wolff, Ekkehard Dreher, Uwe Ernst, Vera Della Casa, Gabriele Pohlig, Federico Graf, R Renato Kaiser.   

Abstract

This randomised, double-blind, multicentric clinical study compared the efficacy and tolerability of the two vaginal antiseptics, 10 mg dequalinium chloride (CAS 522-51-0, Fluomycin N) and 200 mg povidone iodine (CAS 25655-41-8), in a parallel-group design. A total of 180 patients with vaginal infections of varying etiology participated in this study (bacterial vaginosis, fluor vaginalis, vulvo-vaginal candidiasis, trichomoniasis). Patients were randomly allocated to one of the two treatment groups and were treated once per day for 6 days. Control examinations took place 5 to 7 days after the end of treatment, and 3 to 4 weeks after the first control examination. The total symptoms score, a summary score for the clinical symptoms, discharge, burning, pruritus, redness of vulva/vagina, was defined as primary efficacy parameter. The treatments at the first control examination were compared in the full analysis set using the Wilcoxon-Mann-Whitney U-test, 2-sided, thereby proving equivalence of both treatments at the 5% level. Both treatments strongly improved the symptoms of vaginal infections both on short-term and long-term follow-up. Descriptive analysis of the secondary parameters, vaginal pH, degree of purity of the vaginal flora, and number of lactobacilli in the wet mounts, supported the comparable efficacy of both therapies to restore the vaginal milieu. Analysis of the diagnostic subgroups indicated that irrespective of the diagnosis, both treatments improved the efficacy criteria as observed for the entire population. The global assessment of the therapeutic efficacy by investigators and patients supported the results of the efficacy analysis with good to very good ratings in 70-90% of the cases. A good tolerability of both preparations was observed in this study with a low number of adverse events in the test group (5.8%).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404887     DOI: 10.1055/s-0031-1299955

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

Review 1.  Local treatment of vulvovaginal candidosis : general and practical considerations.

Authors:  José das Neves; Eugénia Pinto; Branca Teixeira; Gustavo Dias; Patrocínia Rocha; Teresa Cunha; Bárbara Santos; Maria H Amaral; Maria F Bahia
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 2.  Antiseptics and disinfectants for the treatment of bacterial vaginosis: a systematic review.

Authors:  Hans Verstraelen; Rita Verhelst; Kristien Roelens; Marleen Temmerman
Journal:  BMC Infect Dis       Date:  2012-06-28       Impact factor: 3.090

3.  Susceptibility testing of Atopobium vaginae for dequalinium chloride.

Authors:  Guido Lopes dos Santos Santiago; Philipp Grob; Hans Verstraelen; Florian Waser; Mario Vaneechoutte
Journal:  BMC Res Notes       Date:  2012-03-19

4.  Comparing the Therapy of Otomycosis Using Clotrimazole with Iodine Tincture: A Clinical Trial.

Authors:  Mohammad Reza Mofatteh; Mahboubeh Ahi Fersheh; Fatemeh Nikoomanesh; Mohammad Hasan Namaei
Journal:  Iran J Otorhinolaryngol       Date:  2021-07

Review 5.  Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review.

Authors:  Werner Mendling; Ernst Rainer Weissenbacher; Stefan Gerber; Valdas Prasauskas; Philipp Grob
Journal:  Arch Gynecol Obstet       Date:  2015-10-27       Impact factor: 2.344

Review 6.  Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions.

Authors:  Daniela Machado; Joana Castro; Ana Palmeira-de-Oliveira; José Martinez-de-Oliveira; Nuno Cerca
Journal:  Front Microbiol       Date:  2016-01-20       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.